Acerus Acquires Canadian Rights to Novel Pain Relief Product for Gynecological Procedures from Pharmanest

Pharmaceutical Investing

Acerus Pharmaceuticals (TSX:ASP) today announced that it has entered into an exclusive agreement to commercialize Pharmanest AB (“Pharmanest”) Short Acting Lidocaine product (“SHACT”), a novel pain relief drug device combination in Canada. As quoted in the press release: “This is an excellent partnership for Acerus as SHACT is well-aligned with our strategy of becoming the …

As quoted in the press release:

“This is an excellent partnership for Acerus as SHACT is well-aligned with our strategy of becoming the Canadian leader in women’s health by providing innovative products addressing unmet medical needs. Acerus currently intends to file a new drug submission with Health Canada in the first half of 2019, and, if approved, expects SHACT to be commercialized in the first half of 2020”, said Tricia Symmes, Chief Operating Officer of Acerus.
“This transaction will help broaden our women’s health product portfolio and will leverage our existing salesforce. With SHACT, Acerus continues to build a unique product offering that will help accelerate and diversify our product revenues,” added Ed Gudaitis President and Chief Executive Officer of Acerus.

Click here to read the full press release.

Pharmaceutical Investing